Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimization of Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17

NCT05812157 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Nīmes as lead sponsor.

NCT NCT05812157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05812157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimization of Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17
Lead sponsor
Centre Hospitalier Universitaire de Nīmes
Phase
Not applicable
Overall status
Completed
Start date
October 2, 2023
Completion date
February 23, 2026
Enrollment
76 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

axial spondyloarthritis